DOCSLIB.ORG

Insights Into Krabbe Disease from Structures Of

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Insights Into Krabbe Disease from Structures Of Insights into Krabbe disease from SEE COMMENTARY structures of galactocerebrosidase Janet E. Deanea,1, Stephen C. Grahamb, Nee Na Kimc, Penelope E. Steinc, Rosamund McNairc, M. Begoña Cachón-Gonzálezc, Timothy M. Coxc, and Randy J. Reada,1 aDepartment of Haematology and bClinical Biochemistry, Cambridge Institute for Medical Research, University of Cambridge, Addenbrooke’s Hospital, Hills Road, Cambridge CB2 0XY, United Kingdom; and cDepartment of Medicine, University of Cambridge, Addenbrooke’s Hospital, Hills Road, Cambridge CB2 2QQ, United Kingdom Edited by Gregory A. Petsko, Brandeis University, Waltham, MA, and approved July 22, 2011 (received for review April 8, 2011) Krabbe disease is a devastating neurodegenerative disease charac- profile of patients is highly heterogeneous, often occurring in terized by widespread demyelination that is caused by defects in compound heterozygote patterns, such that the course of the dis- the enzyme galactocerebrosidase (GALC). Disease-causing muta- ease cannot easily be predicted from the genotype at the GALC tions have been identified throughout the GALC gene. However, locus (13–15). As with many other lysosomal storage diseases, a molecular understanding of the effect of these mutations has Krabbe patients with similar or identical genotypes can have var- been hampered by the lack of structural data for this enzyme. Here ied clinical presentations and course of their disease (4). we present the crystal structures of GALC and the GALC-product Here we present the structure of mouse GALC (83% identity complex, revealing a novel domain architecture with a previously with human GALC, Fig. S1) alone and in complex with D-galac- uncharacterized lectin domain not observed in other hydrolases. tose. These structures reveal the presence of a unique domain All three domains of GALC contribute residues to the substrate- arrangement, identify the nature of substrate binding and cataly- binding pocket, and disease-causing mutations are widely distrib- sis, and provide insight into the differing roles of mutations uted throughout the protein. Our structures provide an essential occurring in human Krabbe disease variants. insight into the diverse effects of pathogenic mutations on GALC function in human Krabbe variants and a compelling explanation Results for the severity of many mutations associated with fatal infantile Crystal Structure of GALC. The crystal structure of GALC refined to disease. The localization of disease-associated mutations in the 2.1-Å resolution contains one molecule per asymmetric unit com- structure of GALC will facilitate identification of those patients that prising residues 25 to 668 (Fig. 1 and Table S1); GALC is the would be responsive to pharmacological chaperone therapies. archetype of the carbohydrate-active enzymes (CAZy) glycoside Furthermore, our structure provides the atomic framework for hydrolase family 59 (GH59). The overall fold comprises three the design of such drugs. domains: a central triosephosphate isomerase (TIM) barrel, a β-sandwich domain, and a lectin domain (Fig. 1). The first 24 glycoside hydrolase family 59 ∣ glycosyl hydrolase residues of GALC encode the signal peptide for targeting to the ER that in our construct is replaced with the sequence required rabbe disease, also known as globoid-cell leukodystrophy, is for secretion by HEK293 cells and is cleaved during secretion Kan autosomal recessive neurodegenerative disorder caused (as occurs with the wild-type signal peptide in vivo). The structure by a deficiency of the lysosomal enzyme galactocerebrosidase of GALC reveals that residues 25–40 contribute two β-strands (GALC, EC 3.2.1.46) (1). Defects in GALC that result in reduc- to the β-sandwich domain before forming the ðβ∕αÞ8 TIM barrel tion of enzyme activity lead to the accumulation of the cytotoxic (residues 41–337) that lies at the center of the structure. Residues metabolite psychosine, resulting in demyelination due to the 338–452 then form the remainder of the β-sandwich domain. apoptosis of myelin-forming cells (2, 3). Most patients with Residues 453–471 lie across one face of the structure stretching Krabbe disease suffer from rapidly progressive leukoencephalo- from the β-sandwich to the lectin domain (residues 472–668). The pathy with onset before 6 mo of age and death occurring before interfaces formed between each of the domains of GALC are very 2 2 the age of 2 y (4). Rare attenuated variants of Krabbe disease large: 22% (1;770 Å ) and 15% (1;480 Å ) of the solvent acces- include late-infantile, juvenile, and adult presentations with dis- sible surface areas of the β-sandwich domain and the lectin ease severity and progression being highly variable. The preva- domain, respectively, are buried in their interfaces with the TIM lence of Krabbe disease is approximately 1 in 100,000 births, but barrel. Thus, the domains of GALC are not likely to move relative there is wide variation among countries. Two genetically homo- to each other. genous communities have an extremely high prevalence of infan- The central TIM barrel is composed of eight parallel β-strands tile Krabbe disease with about 1 in 100–150 live births (5). surrounded by α-helices. The connecting loops on the C-terminal Sequence characterization of the human GALC gene and the discovery of the naturally occurring Twitcher mouse model of the disease have contributed to the molecular understanding of Author contributions: J.E.D., P.E.S., M.B.C.-G., T.M.C., and R.J.R. designed research; J.E.D., – S.C.G., N.N.K., R.M., and M.B.C.-G. performed research; J.E.D., S.C.G., T.M.C., and R.J.R. Krabbe disease (6 9). GALC is produced and glycosylated in analyzed data; and J.E.D., S.C.G., N.N.K., P.E.S., M.B.C.-G., T.M.C., and R.J.R. wrote the endoplasmic reticulum (ER)-Golgi complex after which it the paper. is trafficked, via the mannose-6-phosphate (M6P) pathway, to The authors declare no conflict of interest. BIOCHEMISTRY the lysosome (10). GALC is essential for normal catabolism of This article is a PNAS Direct Submission. galactosphingolipids, including the principal lipid component Freely available online through the PNAS open access option. of myelin, galactocerebroside (10). Sphingolipid degradation Data deposition: The atomic coordinates and structure factors have been deposited in the requires the combined action of water-soluble hydrolases and Protein Data Bank, www.pdb.org (PDB ID codes 3zr5 and 3zr6). nonenzymatic sphingolipid activator proteins known as saposins See Commentary on page 15017. (11, 12). 1To whom correspondence may be addressed. E-mail: [email protected] or rjr27@cam. More than 70 mutations in the GALC gene have been asso- ac.uk. ciated with severe clinical phenotypes and these mutations are This article contains supporting information online at www.pnas.org/lookup/suppl/ distributed throughout the sequence of GALC. The mutational doi:10.1073/pnas.1105639108/-/DCSupplemental. www.pnas.org/cgi/doi/10.1073/pnas.1105639108 PNAS ∣ September 13, 2011 ∣ vol. 108 ∣ no. 37 ∣ 15169–15173 Downloaded by guest on October 2, 2021 side of the barrel (proximal to the lectin domain) are generally glycosylation at additional predicted sites in the lectin domain longer than those on the opposite side of the barrel. The β-sand- (N585 and N629). wich domain comprises two twisted β-sheets with a similar topol- ogy to that seen in other glycosyl hydrolases except for a very long Substrate Specificity. GALC catalyses the hydrolysis of the galac- loop that wraps over the top of the TIM barrel. A cysteine residue tosyl moiety from glycosphingolipids such as galactocerebroside in this loop, C378, forms a disulfide bridge with C271 in the TIM and psychosine (Fig. 2A). To better understand the substrate barrel. A calcium ion is bound in the lectin domain of GALC in a binding of GALC, we solved the structure of the enzyme in com- pentagonal bipyramidal configuration (Fig. S2). The lectin do- plex with D-galactose to 2.4-Å resolution (Fig. 2B and Table S1). main of GALC possesses a similar fold and calcium-binding site to that of β-glucanase (PDB ID code 3d6e, rmsd ¼ 2.38 Å over 155 Cα atoms). However, the lectin domain of GALC does not possess the catalytic residues present in the β-glucanase family. The lectin domain of GALC also possesses structural similarity to galectin proteins (PDB ID code 2yv8, rmsd ¼ 2.45 Å over 129 Cα atoms) and other carbohydrate-binding lectins. Residues N284, N363, N387, and N542 displayed electron density for gly- cosylation moieties, and these have been modeled in the GALC structure (Fig. 1). No ordered electron density was observed for Fig. 2. Substrate-binding site of GALC. (A) Schematic diagram of the GALC substrate galactocerebroside. (B) Ribbon diagram of GALC illustrating bound galactose (pink sticks) with domains colored as in Fig. 1. (C) Surface representation of GALC zoomed in on the galactose-binding site, colored F F and oriented as in B.(D) Unbiased difference ( O- C) electron density (green mesh) corresponding to galactose bound to GALC. (E) Active site of GALC illustrating the relevant atomic distances (purple dashed lines) between Fig. 1. Structure of GALC shown in two orthogonal views. Ribbon diagram the bound galactose (pink sticks) and the proposed catalytic residues: the of GALC colored by domain: β-sandwich (red), TIM barrel (blue), linker nucleophile (E258, blue sticks) and the proton donor (E182, blue sticks). (orange), and lectin domain (green). The disulfide bond (yellow spheres), (F) Substrate specificity for galactose- (pink sticks) rather than glucose- calcium ion (gray sphere), and glycosylation moieties (violet sticks) are (yellow sticks) containing glycolipids is conferred by W291 and T93 (blue shown. The N and C termini are marked by labeled circles (Top). sticks). 15170 ∣ www.pnas.org/cgi/doi/10.1073/pnas.1105639108 Deane et al.
Load more

Recommended publications
  • Oral Ambroxol Increases Brain Glucocerebrosidase Activity in a Nonhuman Primate
    Received: 17 November 2016 | Revised: 24 January 2017 | Accepted: 12 February 2017 DOI 10.1002/syn.21967 SHORT COMMUNICATION Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate Anna Migdalska-Richards1 | Wai Kin D. Ko2 | Qin Li2,3 | Erwan Bezard2,3,4,5 | Anthony H. V. Schapira1 1Department of Clinical Neurosciences, Institute of Neurology, University College Abstract London, NW3 2PF, United Kingdom Mutations in the glucocerebrosidase 1 (GBA1) gene are related to both Parkinson disease (PD) and 2Motac Neuroscience, Manchester, United Gaucher disease (GD). In both cases, the condition is associated with deficiency of glucocerebrosi- Kingdom dase (GCase), the enzyme encoded by GBA1. Ambroxol is a small molecule chaperone that has 3 Institute of Laboratory Animal Sciences, been shown in mice to cross the blood-brain barrier, increase GCase activity and reduce alpha- China Academy of Medical Sciences, Beijing synuclein protein levels. In this study, we analyze the effect of ambroxol treatment on GCase City, People’s Republic of China activity in healthy nonhuman primates. We show that daily administration of ambroxol results in 4University de Bordeaux, Institut des Maladies Neurodeg en eratives, UMR 5293, increased brain GCase activity. Our work further indicates that ambroxol should be investigated as Bordeaux F-33000, France a novel therapy for both PD and neuronopathic GD in humans. 5CNRS, Institut des Maladies Neurodeg en eratives, UMR 5293, Bordeaux F-33000, France KEYWORDS Correspondence ambroxol, glucocerebrosidase,
    [Show full text]
  • Mannosidases Are the Putative Catabolic Enzymes Which
    THE CHARACTERIZATION OF A NOVEL HUMAN CORE-SPECIFIC LYSOSOMAL α1-6MANNOSIDASE INVOLVED IN N-GLYCAN CATABOLISM by CHAEHO PARK (Under the Direction of Kelley W. Moremen) ABSTRACT In humans and rodents lysosomal catabolism of Man3GlcNAc2 core N-glycan structures results from the concerted actions of exoglycosidases including the broad specificity lysosomal α- mannosidase (LysMan), a core-specific α1-6mannosidase, and β-mannosidase, as well as the core chitobiose cleavage by an di-N-acetylchitobiase. In ungulates and carnivora, both the chitobiase and the α1-6mannosidase enzyme activities are absent suggesting a co-regulation of the two enzymes. We describe here the cloning, expression, purification and characterization of the human core-specific α1-6mannosidase with similarity to members of the glycosylhydrolase family 38. The recombinant enzyme had a pH optimum of 4.0, was potently inhibited by swainsonine and 1,4-dideoxy1,4-imino-D-mannitol, and was stimulated by Co+2. NMR-based time course substrate specificity studies comparing the α1-6mannosidase with human LysMan revealed that the former enzyme selectively cleaved the α1-6mannose residue from Man3GlcNAc, but not Man3GlcNAc2 or other larger high mannose structures, indicating the requirement for chitobiase action prior to α1-6mannosidase cleavage. In contrast, LysMan cleaved all of the α-linked mannose residues from Man9-5GlcNAc2, Man3GlcNAc2, or Man3GlcNAc structures except the core α1-6mannose residue. Transcripts encoding the α1-6mannosidase were ubiquitously expressed in human tissues and expressed sequence tag searches in various mammalian species demonstrated a similar distribution in species-specific expression as the chitobiase. No expressed sequence tags were identified for bovine α1-6mannosidase despite the identification of two homologs in the bovine genome.
    [Show full text]
  • GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies
    International Journal of Molecular Sciences Review GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies Andrés Felipe Leal 1 , Eliana Benincore-Flórez 1, Daniela Solano-Galarza 1, Rafael Guillermo Garzón Jaramillo 1 , Olga Yaneth Echeverri-Peña 1, Diego A. Suarez 1,2, Carlos Javier Alméciga-Díaz 1,* and Angela Johana Espejo-Mojica 1,* 1 Institute for the Study of Inborn Errors of Metabolism, Faculty of Science, Pontificia Universidad Javeriana, Bogotá 110231, Colombia; [email protected] (A.F.L.); [email protected] (E.B.-F.); [email protected] (D.S.-G.); [email protected] (R.G.G.J.); [email protected] (O.Y.E.-P.); [email protected] (D.A.S.) 2 Faculty of Medicine, Universidad Nacional de Colombia, Bogotá 110231, Colombia * Correspondence: [email protected] (C.J.A.-D.); [email protected] (A.J.E.-M.); Tel.: +57-1-3208320 (ext. 4140) (C.J.A.-D.); +57-1-3208320 (ext. 4099) (A.J.E.-M.) Received: 6 July 2020; Accepted: 7 August 2020; Published: 27 August 2020 Abstract: GM2 gangliosidoses are a group of pathologies characterized by GM2 ganglioside accumulation into the lysosome due to mutations on the genes encoding for the β-hexosaminidases subunits or the GM2 activator protein. Three GM2 gangliosidoses have been described: Tay–Sachs disease, Sandhoff disease, and the AB variant. Central nervous system dysfunction is the main characteristic of GM2 gangliosidoses patients that include neurodevelopment alterations, neuroinflammation, and neuronal apoptosis. Currently, there is not approved therapy for GM2 gangliosidoses, but different therapeutic strategies have been studied including hematopoietic stem cell transplantation, enzyme replacement therapy, substrate reduction therapy, pharmacological chaperones, and gene therapy.
    [Show full text]
  • Genetics and Epigenetics in Parkinson´S Disease
    Genetics and epigenetics in Parkinson´s disease. Luis Navarro Sánchez. Thesis supervisor: Jordi Pérez Tur. Unitat de Genètica Molecular, Institut de Biomedicina de València, CSIC. Doctoral studies: Biotechnology. Facultat de Ciències Biològiques, Universitat de València. Tras preguntas y más preguntas y miedo y nervios y ansiedad y más ansiedad y bloqueos y periodos depresivos y tristeza y mucha, pero mucha, mierda… acabas. Tarde y reventado, pero acabas. Y lo único que quieres es pasar página y que esto no te pase más nunca. ¿Y? Pues que te surgen más preguntas y más miedo y más nervios…. Y te das cuenta de que vives en un puto bucle científico que se está comiendo tu vida. ¿Y? No lo sé, estoy en ello. Terapia y medicación, supongo. Aunque la autodestrucción y los realities son muy apetecibles. En primer lugar, las formalidades. Gracias Jordi por dejarme que trabajara en la UGM. A estas alturas, creo que los dos nos habremos planteado muchas veces si fue una buena decisión, pero ya da igual. A continuación, el momento pasteleo, aunque si no sé dar un abrazo, no penséis que esto me va a salir fluido. Y menos aún, estando sobrio. Y que no se me enfade nadie si no he puesto su nombre o si no he escrito un parrafazo lacrimógeno y azucarado exaltando la belleza de nuestra relación. Si dejo que leas esto, significa que también eres importante para mí. Lo mejor de todo este tiempo sois, de calle, vosotros y vosotras: Bea, Carolina, Eva, Fer, LauraA, LauraG, María, Marta, Pili, Silvia, Vicente/Andreu y VicenteH.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Molecular Cloning and Knockdown of Galactocerebrosidase in Zebrafish
    Biochimica et Biophysica Acta 1842 (2014) 665–675 Contents lists available at ScienceDirect Biochimica et Biophysica Acta journal homepage: www.elsevier.com/locate/bbadis Molecular cloning and knockdown of galactocerebrosidase in zebrafish: New insights into the pathogenesis of Krabbe's disease Daniela Zizioli a,1, Michela Guarienti a,1,ChiaraTobiab, Giuseppina Gariano b, Giuseppe Borsani c, Roberto Bresciani a,RobertoRoncab, Edoardo Giacopuzzi c, Augusto Preti a, Germano Gaudenzi d, Mirella Belleri b, Emanuela Di Salle b, Gemma Fabrias e, Josefina Casas e,DomenicoRibattif,g, Eugenio Monti a,MarcoPrestab,⁎ a Unit of Biotechnology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy b Unit of Oncology and Experimental Immunology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy c Unit of Biology and Genetics, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy d Department of Biology, University of Milan, Milan, Italy e Research Unit on Bioactive Molecules (RUBAM), Department of Biomedicinal Chemistry, Institute for Advanced Chemistry of Catalonia (IQAC), Spanish Council for Scientific Research (CSIC), Barcelona, Spain f Department of Basic Biomedical Sciences, Unit of Human Anatomy and Histology, University of Bari, Bari, Italy g National Cancer Institute, Giovanni Paolo II, Bari, Italy article info abstract Article history: The lysosomal hydrolase galactocerebrosidase (GALC) catalyzes the removal of galactose from galactosylceramide Received 2 September 2013 and from other sphingolipids. GALC deficiency is responsible for globoid cell leukodystrophy (GLD), or Krabbe's Received in revised form 17 December 2013 disease, an early lethal inherited neurodegenerative disorder characterized by the accumulation of the neurotoxic Accepted 15 January 2014 metabolite psychosine in the central nervous system (CNS).
    [Show full text]
  • Glycosphingolipids Are Modulators of Disease Pathogenesis in Amyotrophic Lateral Sclerosis
    Glycosphingolipids are modulators of disease pathogenesis in amyotrophic lateral sclerosis James C. Dodgea,1, Christopher M. Treleavena, Joshua Pachecoa, Samantha Coopera,ChannaBaoa, Marissa Abrahama, Mandy Cromwella, S. Pablo Sardia, Wei-Lien Chuanga, Richard L. Sidmanb,1,2,SengH.Chenga, and Lamya S. Shihabuddina aRare Diseases Science, Genzyme, a Sanofi Company, Framingham, MA 01701; and bBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215 Contributed by Richard L. Sidman, May 7, 2015 (sent for review January 12, 2015; reviewed by David V. Schaffer) Recent genetic evidence suggests that aberrant glycosphingolipid mediates the hydrolysis of Cer, are linked to forms of spinal metabolism plays an important role in several neuromuscular muscular atrophy that are not caused by the more frequent mu- diseases including hereditary spastic paraplegia, hereditary sen- tations in the survival motor neuron 1 gene (non-5q SMA) (15). sory neuropathy type 1, and non-5q spinal muscular atrophy. Here, Moreover, hereditary spastic paraplegia (HSP), a disease with cor- we investigated whether altered glycosphingolipid metabolism is ticospinal tract and in some cases, spinal cord MN degeneration, a modulator of disease course in amyotrophic lateral sclerosis (ALS). is attributed to mutations in GM2 synthase (16) and the non- Levels of ceramide, glucosylceramide, galactocerebroside, lactosyl- lysosomal glucosylceramidase, GBA2 (17). Last, patients with adult- ceramide, globotriaosylceramide, and the gangliosides GM3 and onset Tay-Sachs disease (GM2 gangliosidosis), a disease triggered GM1 were significantly elevated in spinal cords of ALS patients. by a deficiency in hexosaminidase (HEX), a lysosomal enzyme Moreover, enzyme activities (glucocerebrosidase-1, glucocerebrosi- that hydrolyzes GM2 to GM3, have been reported in some in- dase-2, hexosaminidase, galactosylceramidase, α-galactosidase, and stances to display a disease phenotype that closely mimics ALS β-galactosidase) mediating glycosphingolipid hydrolysis were also (18–20).
    [Show full text]
  • Polymorphisms in the Glucocerebrosidase Gene And
    BMC Medical Genetics BioMed Central Technical advance Open Access Polymorphisms in the glucocerebrosidase gene and pseudogene urge caution in clinical analysis of Gaucher disease allele c.1448T>C (L444P) Justin T Brown*, Cora Lahey, Walairat Laosinchai-Wolf and Andrew G Hadd Address: Asuragen, Inc., Austin, Texas, USA Email: Justin T Brown* - [email protected]; Cora Lahey - [email protected]; Walairat Laosinchai- Wolf - [email protected]; Andrew G Hadd - [email protected] * Corresponding author Published: 03 August 2006 Received: 17 March 2006 Accepted: 03 August 2006 BMC Medical Genetics 2006, 7:69 doi:10.1186/1471-2350-7-69 This article is available from: http://www.biomedcentral.com/1471-2350/7/69 © 2006 Brown et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: Gaucher disease is a potentially severe lysosomal storage disorder caused by mutations in the human glucocerebrosidase gene (GBA). We have developed a multiplexed genetic assay for eight diseases prevalent in the Ashkenazi population: Tay-Sachs, Gaucher type I, Niemann- Pick types A and B, mucolipidosis type IV, familial dysautonomia, Canavan, Bloom syndrome, and Fanconi anemia type C. This assay includes an allelic determination for GBA allele c.1448T>C (L444P). The goal of this study was to clinically evaluate this assay. Methods: Biotinylated, multiplex PCR products were directly hybridized to capture probes immobilized on fluorescently addressed microspheres. After incubation with streptavidin- conjugated fluorophore, the reactions were analyzed by Luminex IS100.
    [Show full text]
  • GALC Gene Galactosylceramidase
    GALC gene galactosylceramidase Normal Function The GALC gene provides instructions for making an enzyme called galactosylceramidase. Through a process called hydrolysis, this enzyme uses water molecules to break down certain fats called galactolipids, which are found primarily in the nervous system and kidneys. Within cells, galactosylceramidase is found in enzyme-filled sacs called lysosomes where it hydrolyzes specific galactolipids, including galactosylceramide and psychosine. Galactosylceramide is an important component of myelin, the protective covering around certain nerve cells that ensures the rapid transmission of nerve impulses. Its breakdown by galactosylceramidase is part of the normal turnover of myelin that occurs throughout life. Psychosine, which is toxic to cells, forms during the production of myelin and is quickly broken down by galactosylceramidase. Under normal conditions, tissues contain very little psychosine. Health Conditions Related to Genetic Changes Krabbe disease More than 200 GALC gene mutations that cause Krabbe disease have been identified. Krabbe disease is a brain disorder that usually begins in infancy (infantile Krabbe disease) and causes movement and eating problems, impaired development, and seizures. The most common mutation in affected individuals of European ancestry ( often called 30-kb del) deletes a large segment of the GALC gene. Other mutations insert additional DNA building blocks (nucleotides) into the GALC gene, delete a small number of nucleotides from the gene, or replace single nucleotides with incorrect nucleotides. These GALC gene mutations severely reduce or eliminate the activity of the galactosylceramidase enzyme. As a result, galactosylceramide and psychosine cannot be broken down. The accumulation of these galactolipids causes damage to myelin- forming cells, which impairs the formation of myelin and leads to the loss of myelin ( demyelination) in the nervous system.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,689,046 B2 Mayall Et Al
    USOO9689046B2 (12) United States Patent (10) Patent No.: US 9,689,046 B2 Mayall et al. (45) Date of Patent: Jun. 27, 2017 (54) SYSTEM AND METHODS FOR THE FOREIGN PATENT DOCUMENTS DETECTION OF MULTIPLE CHEMICAL WO O125472 A1 4/2001 COMPOUNDS WO O169245 A2 9, 2001 (71) Applicants: Robert Matthew Mayall, Calgary (CA); Emily Candice Hicks, Calgary OTHER PUBLICATIONS (CA); Margaret Mary-Flora Bebeselea, A. et al., “Electrochemical Degradation and Determina Renaud-Young, Calgary (CA); David tion of 4-Nitrophenol Using Multiple Pulsed Amperometry at Christopher Lloyd, Calgary (CA); Lisa Graphite Based Electrodes', Chem. Bull. “Politehnica” Univ. Kara Oberding, Calgary (CA); Iain (Timisoara), vol. 53(67), 1-2, 2008. Fraser Scotney George, Calgary (CA) Ben-Yoav. H. et al., “A whole cell electrochemical biosensor for water genotoxicity bio-detection”. Electrochimica Acta, 2009, 54(25), 6113-6118. (72) Inventors: Robert Matthew Mayall, Calgary Biran, I. et al., “On-line monitoring of gene expression'. Microbi (CA); Emily Candice Hicks, Calgary ology (Reading, England), 1999, 145 (Pt 8), 2129-2133. (CA); Margaret Mary-Flora Da Silva, P.S. et al., “Electrochemical Behavior of Hydroquinone Renaud-Young, Calgary (CA); David and Catechol at a Silsesquioxane-Modified Carbon Paste Elec trode'. J. Braz. Chem. Soc., vol. 24, No. 4, 695-699, 2013. Christopher Lloyd, Calgary (CA); Lisa Enache, T. A. & Oliveira-Brett, A. M., "Phenol and Para-Substituted Kara Oberding, Calgary (CA); Iain Phenols Electrochemical Oxidation Pathways”, Journal of Fraser Scotney George, Calgary (CA) Electroanalytical Chemistry, 2011, 1-35. Etesami, M. et al., “Electrooxidation of hydroquinone on simply prepared Au-Pt bimetallic nanoparticles'. Science China, Chem (73) Assignee: FREDSENSE TECHNOLOGIES istry, vol.
    [Show full text]
  • Impaired Β-Glucocerebrosidase Activity and Processing in Frontotemporal Dementia Due to Progranulin Mutations Andrew E
    Arrant et al. Acta Neuropathologica Communications (2019) 7:218 https://doi.org/10.1186/s40478-019-0872-6 RESEARCH Open Access Impaired β-glucocerebrosidase activity and processing in frontotemporal dementia due to progranulin mutations Andrew E. Arrant1,2*, Jonathan R. Roth1, Nicholas R. Boyle1, Shreya N. Kashyap1, Madelyn Q. Hoffmann1, Charles F. Murchison1,3, Eliana Marisa Ramos4, Alissa L. Nana5, Salvatore Spina5, Lea T. Grinberg5,6, Bruce L. Miller5, William W. Seeley5,6 and Erik D. Roberson1,7* Abstract Loss-of-function mutations in progranulin (GRN) are a major autosomal dominant cause of frontotemporal dementia. Most pathogenic GRN mutations result in progranulin haploinsufficiency, which is thought to cause frontotemporal dementia in GRN mutation carriers. Progranulin haploinsufficiency may drive frontotemporal dementia pathogenesis by disrupting lysosomal function, as patients with GRN mutations on both alleles develop the lysosomal storage disorder neuronal ceroid lipofuscinosis, and frontotemporal dementia patients with GRN mutations (FTD-GRN) also accumulate lipofuscin. The specific lysosomal deficits caused by progranulin insufficiency remain unclear, but emerging data indicate that progranulin insufficiency may impair lysosomal sphingolipid- metabolizing enzymes. We investigated the effects of progranulin insufficiency on sphingolipid-metabolizing enzymes in the inferior frontal gyrus of FTD-GRN patients using fluorogenic activity assays, biochemical profiling of enzyme levels and posttranslational modifications, and quantitative neuropathology. Of the enzymes studied, only β-glucocerebrosidase exhibited impairment in FTD-GRN patients. Brains from FTD-GRN patients had lower activity than controls, which was associated with lower levels of mature β-glucocerebrosidase protein and accumulation of insoluble, incompletely glycosylated β-glucocerebrosidase. Immunostaining revealed loss of neuronal β- glucocerebrosidase in FTD-GRN patients.
    [Show full text]
  • Folding-TIM Barrel
    Protein Folding Practical September 2011 Folding up the TIM barrel Preliminary Examine the parallel beta barrel that you constructed, noting the stagger of the strands that was needed to connect the ends of the 8-stranded parallel beta sheet into the 8-stranded beta barrel. Notice that the stagger dictates which side of the sheet is on the inside and which is on the outside. This will be key information in folding the complete TIM linear peptide into the TIM barrel. Assembling the full linear peptide 1. Make sure the white beta strands are extended correctly, and the 8 yellow helices (with the green loops at each end) are correctly folded into an alpha helix (right handed with H-bonds to the 4th ahead in the chain). 2. starting with a beta strand connect an alpha helix and green loop to make the blue-red connecting peptide bond. Making sure that you connect the carbonyl (red) end of the beta strand to the amino (blue) end of the loop-helix-loop. Secure the just connected peptide bond bond with a twist-tie as shown. 3. complete step 2 for all beta strand/loop-helix-loop pairs, working in parallel with your partners 4. As pairs are completed attach the carboxy end of the strand- loop-helix-loop to the amino end of the next strand-loop-helix-loop module and secure the new peptide bond with a twist-tie as before. Repeat until the full linear TIM polypeptide chain is assembled. Make sure all strands and helices are still in the correct conformations.
    [Show full text]